Myriad Genetics Presents a Revolutionary Study on Prenatal Testing
Myriad Genetics, Inc. (NASDAQ: MYGN), a frontrunner in genetic testing and precision medicine, recently showcased groundbreaking results from its innovative research at a notable medical conference. This is not just a remarkable achievement for the company but a significant step forward in prenatal care.
A Major Milestone in Prenatal Screening
At the annual Society for Maternal-Fetal Medicine Conference, Myriad Genetics revealed its findings on the Prequel with AMPLIFY™ technology, a novel prenatal cell-free DNA screening method. This study, recognized with the coveted “Dru Carlson Memorial Award for Best Research in Ultrasound and Genetics,” suggests that reliable genetic screening can be performed as early as eight weeks into pregnancy—a significant advancement considering traditional practices typically start at nine to ten weeks.
Understanding Fetal Fraction for Improved Results
The essence of this study lies in the concept of fetal fraction (FF), the portion of placental cfDNA in maternal blood that indicates fetal health. Early in gestation, this FF can be too low for accurate analysis, a problem the new technology aims to solve. Research results indicated that Prequel with AMPLIFY could enhance FF levels to an impressive average of 12.5%, significantly reducing the no-call rate to below 0.5% for screenings conducted between eight and ten weeks gestation.
A Statement from the Chief Scientific Officer
Dale Muzzey, PhD, Chief Scientific Officer at Myriad Genetics, emphasized the positive implications of this advancement. He stated, “Being able to assess the risks for chromosomal disorders at eight weeks of pregnancy is groundbreaking. It allows us to provide critical information much earlier in a patient's journey, enhancing the options available for timely diagnostic testing.”
Sharing New Insights at the Conference
The findings will be presented during an anticipated plenary session at the conference, with Dr. Lorraine Dugoff leading the presentation. This opportunity underscores Myriad's commitment to advancing genetic testing methodologies, further enlightening healthcare providers and patients alike.
Exploring the Study's Design
The multi-site study aimed to explore the feasibility of obtaining high-quality results at such an early stage of pregnancy. Participants provided blood samples at two intervals: between six to nine weeks and at ten weeks or later, allowing comprehensive comparison. This design revealed that the Prequel system at eight weeks offers reliable FF levels comparable to those usually observed at more advanced gestational stages.
Additional Contributions to Maternal-Fetal Medicine
Myriad Genetics is also set to present additional research at the conference focusing on maternal mosaicism and its impact on fetal sex chromosome aneuploidy screening. Dr. Muzzey will share insights on the development of the new “depth trajectory” screening method, aiming to enhance predictive values in sex chromosome abnormalities. This underscores the company’s continued investment in improving prenatal genetic screening accuracy.
The Importance of the Prequel Prenatal Screen
The Prequel® Prenatal Screen stands out as the only cfDNA test available as early as eight weeks of gestation, powered by AMPLIFY™ technology. This groundbreaking method not only increases fetal fraction but also equips healthcare professionals with vital information regarding potential chromosomal issues much sooner than was previously possible.
The Mission of Myriad Genetics
As a leading name in genetic testing and precision medicine, Myriad Genetics remains devoted to enhancing health and well-being. The company is determined to deliver comprehensive tests that improve patient care and reduce healthcare costs through precise genetic insights.
Frequently Asked Questions
What is the significance of this study by Myriad Genetics?
This study allows prenatal screening to occur as early as eight weeks, improving risk assessment for chromosomal disorders significantly compared to traditional methods.
How does Prequel with AMPLIFY enhance prenatal testing?
It increases the fetal fraction in maternal blood samples, allowing for accurate results at earlier gestational ages than previously possible.
What does this mean for expectant mothers?
Expectant mothers can receive critical information about their pregnancy status much earlier, facilitating timely decision-making regarding their care.
Who presented this research at the SMFM conference?
Dr. Lorraine Dugoff from the University of Pennsylvania led the presentation detailing the groundbreaking findings.
How does Myriad Genetics contribute to the healthcare field?
Myriad Genetics focuses on genetic testing and precision medicine, providing services that enhance decision-making in treatment and disease risk assessments across various medical specialties.
